Alembic Ltd. News and Updates

Keep track of all breaking news on Alembic Ltd. from all sources in a single place.

Load latest

Alembic Ltd.

18 Aug 2022

117.26

-1.23%

This multibagger stock sets record date for 90% dividend

livemint

Alembic Ltd is a real estate-related small cap company with a market cap of 1,982.36 Crore.

Alembic Ltd. is trading below its 200 day SMA of 117.7

Alembic Ltd.

10 Jun 2022

117.26

-1.23%

Alembic gets USFDA nod for cancer treatment drug

Moneycontrol

The company has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Dasatinib tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, Alembic Pharmaceuticals said in a statement.

Alembic Ltd. is trading below its 200 day SMA of 117.7

Alembic Ltd.

11 May 2022

117.26

-1.23%

Alembic gets final USFDA nod for medication to treat bronchoconstriction

Business Standard

Alembic Pharmaceuticals Ltd on Wednesday said it has received final approval from the US health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial, the company said in a statement. The approved ANDA is therapeutically equivalent to the reference-listed drug product (RLD), Brovana inhalation solution, 15 mcg/2 mL, of Sunovion Pharmaceuticals Inc, it added. Arformoterol Tartrate inhalation solution is indicated for long-term, twice daily administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, the company said. This ANDA has...

Alembic Ltd. is trading below its 200 day SMA of 117.7

Alembic Ltd.

06 May 2022

117.26

-1.23%

Alembic Consolidated March 2022 Net Sales at Rs 18.24 crore, down 36.88% Y-o-Y

Moneycontrol

NULL

Alembic Ltd. is trading below its 200 day SMA of 117.7

Alembic Standalone March 2022 Net Sales at Rs 17.40 crore, down 39.04% Y-o-Y

Moneycontrol | 06 May 2022

Alembic Ltd.

04 May 2022

117.26

-1.23%

Alembic arm receives final USFDA approval for generic fever blisters drug

Business Standard

Alembic Pharmaceuticals on Wednesday said its wholly-owned arm Aleor Dermaceuticals has received final approval from the US health regulator for its generic Docosanol cream indicated for cold sore/fever blisters on the face or lips. The final approval granted by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Docosanol cream, 10 per cent (over the counter), the company said in a regulatory filing. The approved ANDA is therapeutically equivalent to the reference listed drug product Abreva Cream, 10 per cent (OTC) of GlaxoSmithKline Consumer Healthcare, it added. Citing IQVIA data, Alembic said Docosanol cream, 10 per cent (OTC) has an estimated market size of USD 60 million for 12 months ending December 2021. Alembic has received a cumulative total of 166 ANDA approvals (142 final approvals and 24 tentative approvals) from the USFDA, it added.

Alembic Ltd. is trading above its 150 day SMA of 112.7

Alembic Ltd.

25 Apr 2022

117.26

-1.23%

Alembic arm Aleor Dermaceuticals gets USFDA nod for plaque psoriasis treatment foam

Moneycontrol

The approval granted by the US Food Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Clobetasol Propionate foam, 0.05 per cent, Alembic said in a regulatory filing.

Alembic Ltd. is trading above its 150 day SMA of 112.7

Alembic Ltd.

20 Apr 2022

117.26

-1.23%

Alembic gets USFDA nod to market generic drug

Moneycontrol

The company has received tentative approval from the US Food Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for lvabradine tablets (5 mg and 7.5 mg), Alembic Pharmaceuticals said in a regulatory filing.